BOHAI SECURITIES·2026-02-05 07:48Industry Overview - The report highlights the recent release of the "Implementation Regulations of the Drug Administration Law of the People's Republic of China" and the issuance of opinions by nine departments to promote high-quality development in the drug retail industry [21][23][25] - The sixth batch of national procurement for high-value medical consumables has been opened for bidding, indicating ongoing efforts to regulate and enhance the medical supply chain [21][22] Industry Data - In December, the Consumer Price Index (CPI) for healthcare was 101.8, with a year-on-year increase of 1.8% and a month-on-month increase of 0.1% [26] - The Producer Price Index (PPI) for pharmaceutical manufacturing was 96.1, showing a year-on-year decrease of 3.9% and a month-on-month decrease of 0.2% [37] - For the entire year of 2025, the cumulative operating income of the pharmaceutical manufacturing industry was 24,870.0 billion, a year-on-year decrease of 1.2%, while the cumulative total profit was 3,490.0 billion, a year-on-year increase of 2.7% [39] Company Announcements - Hengrui Medicine received drug registration approval and had several drugs included in the list of breakthrough therapy designations, indicating a strong pipeline and regulatory progress [62][67] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, which includes significant upfront and milestone payments [68] - Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, a dual-specific antibody drug, which includes substantial upfront and potential milestone payments [69] Market Performance - In January, the Shanghai Composite Index rose by 3.76%, while the Shenzhen Component Index increased by 5.03%. The SW Pharmaceutical and Biological Index rose by 3.14%, with all sub-sectors showing positive growth [74] - The SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.97, with a valuation premium of 258% relative to the CSI 300 [77] Monthly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, particularly in light of recent developments in brain-computer interfaces and AI applications [84] - The report maintains a "neutral" rating for the industry and recommends a "buy" rating for Hengrui Medicine and an "accumulate" rating for WuXi AppTec [84]